Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer

[1]  S. Loi,et al.  Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Sung-Bae Kim,et al.  Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy , 2019, Annals of Oncology.

[3]  H. Horlings,et al.  Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes , 2019, Breast Cancer Research.

[4]  Jan Baumbach,et al.  Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..

[5]  Benjamin Haibe-Kains,et al.  Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers , 2019, The Journal of clinical investigation.

[6]  Z. Szallasi,et al.  Neoantigen-directed immune escape in lung cancer evolution , 2019, Nature.

[7]  Emanuela Scarpi,et al.  Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients12 , 2019, Translational oncology.

[8]  A. Brandes,et al.  Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Kurosumi,et al.  Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis , 2019, Oncology letters.

[11]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[12]  Marieke E. Ijsselsteijn,et al.  Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2018, bioRxiv.

[13]  E. King,et al.  Pan-cancer deconvolution of tumour composition using DNA methylation , 2018, Nature Communications.

[14]  T. Khoury,et al.  Tumor-Infiltrating Lymphocytes in Breast Cancer: Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies , 2018, American journal of clinical pathology.

[15]  Chengzhong Ye,et al.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.

[16]  P. Heikkilä,et al.  Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study , 2018, Breast Cancer Research and Treatment.

[17]  L. Opitz,et al.  Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer , 2018, Journal of Translational Medicine.

[18]  L. Opitz,et al.  Correction to: Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer , 2018, Journal of Translational Medicine.

[19]  A. Mangia,et al.  Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers , 2018, Translational oncology.

[20]  M. Ringnér,et al.  Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation , 2018, bioRxiv.

[21]  Z. Trajanoski,et al.  Quantifying tumor-infiltrating immune cells from transcriptomics data , 2018, Cancer Immunology, Immunotherapy.

[22]  T. Tramm,et al.  Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists , 2018, Acta oncologica.

[23]  M. Kok,et al.  Targeting immune checkpoints in breast cancer: an update of early results , 2017, ESMO Open.

[24]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[25]  Gianluca Bontempi,et al.  DNA methylation–based immune response signature improves patient diagnosis in multiple cancers , 2017, The Journal of clinical investigation.

[26]  C. Sotiriou,et al.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer , 2017, Modern Pathology.

[27]  D. Speiser,et al.  Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data , 2017, bioRxiv.

[28]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[29]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[30]  Carlos Caldas,et al.  Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study , 2016, PLoS medicine.

[31]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[32]  E. Birney,et al.  Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration , 2016, Nature Communications.

[33]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[34]  Patrik L. Ståhl,et al.  Visualization and analysis of gene expression in tissue sections by spatial transcriptomics , 2016, Science.

[35]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[36]  Fei Yang,et al.  Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group , 2016, Annals of Surgical Oncology.

[37]  J. Martens,et al.  Genomic profiling of CHEK2*1100delC-mutated breast carcinomas , 2015, BMC Cancer.

[38]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[39]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[41]  Alexander van Oudenaarden,et al.  Spatially resolved transcriptomics and beyond , 2014, Nature Reviews Genetics.

[42]  E. Zhou,et al.  Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer , 2014, PloS one.

[43]  C. Denkert,et al.  Tumor-infiltrating lymphocytes in breast cancer , 2014, Oncoimmunology.

[44]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. S. Hedayat,et al.  Statistical Tools for Measuring Agreement , 2011 .

[46]  J. Nesland,et al.  Limitations of tissue microarrays compared with whole tissue sections in survival analysis. , 2010, Oncology letters.

[47]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[48]  F. B. Sørensen,et al.  Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. , 2008, Acta oncologica.

[49]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[50]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[51]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[52]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[53]  E. Elgabry,et al.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.

[54]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.